Back to resultsActiste® Diabetes Management as a Service (ADMS) Clinical Investigation (ADMSUK01)
Primary Purpose
Diabetes type1, Diabetes type2
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Device: Actiste 1.0 and the Companion app with TBL Backend
Sponsored by
About this trial
This is an interventional treatment trial for Diabetes type1 focused on measuring Diabetes Management, HbA1c, Patient, Patient satisfaction
Eligibility Criteria
Inclusion Criteria:
- Provision of informed consent
- Adult males and females =18 years old
- Diagnosed with diabetes I or II, since = 6 months prior to entering the investigation, according to investigator judgement
- Currently using insulin as a component of the diabetes therapy, Sanofi Lantus insulin (glargine U100 insulin incartridge or disposable pen)± any form or manufacturer of oral antidiabetic drugs (OADs)/bolus insulin regimen/GLP-1RA
- HbA1c 64-86mmol/mol in the last 30 days
- Patients using Self-Monitoring of Blood Glucose (SMBG) = 1 month prior to entering the investigation
- Able to use smartphone (iOS or Android)independently, according to investigator judgement
- Currently using a system compatible smartphone (Android and iOS smartphones: iOS platform versions from 12.0 to 14.x and Android platform versions from 5.1 to 11.x
- Able to use the device independently, according to investigator judgement
Exclusion Criteria:
- Impaired vision affecting ability to use investigation device or smartphone, according to investigator judgement
- Patients using a flash glucose monitor, continuous glucose monitor and/ or insulin pump
- Pregnancy or lactation at time of study participation.
- Physical or mental impairment affecting subjects' ability to use the device, per investigator judgement
- Person not suitable for the investigation according to the investigator judgement.
Sites / Locations
- Salford Royal Hospital Northern Care Alliance NHS Foundation Trust
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Experimental: Single-Arm
Arm Description
This is a prospective, single-arm, post-market study to verify clinical performance, treatment satisfaction and adherence, and safety of Actiste 1.0 (Actiste) and the Companion app with TBL Backend when used as intended by subjects diagnosed with T1DM or T2DM.
Outcomes
Primary Outcome Measures
Diabetes Treatment Satisfaction Questionnaire (change, DTSQc), at 3 months
The Diabetes Treatment Satisfaction Questionnaire (Change, DTSQc) will be completed during the on-site visit at 3 months. The DTSQc is a modified version of the DTSQs designed to overcome ceiling effects and to detect changes in treatment satisfaction. Answers on a 7 graded scale from -3 to 3. In majority, higher score means better outcome.
Secondary Outcome Measures
Percentage and absolute change in HbA1cat 3 and 6 months, compared to baseline
During each on site visit, glycosylated haemoglobin(HbA1c) will be assessed. A blood sample will be taken by the site staff and HbA1c will be assessed per clinical routine at the site.
Percentage and absolute change in fasting blood glucose at 3 and 6 months, compared to baseline
Fasting glucose will be assessed per standard of care at the investigation site. Fasting glucose will be assessed using the Actiste device at least 4 times in the last 10 days (assessment period) before the investigation visit. The final data will be a mean of the measurements during the assessment period. The data will be extracted by the patient to a PDF file and provided to site 2 days before the visit. Site will ask what day and time the fasting blood glucose data was assessed. The data will also be summarised at the end of the investigation and the interim analysis with data from the Companion app and TBL Backend.
Absolute and percentage change in DTSQ (Status) at 6 months, compared to baseline
The Diabetes Treatment Satisfaction Questionnaire (Status, DTSQs) will be completed during the on-sitevisits at baseline and at 6 months.The DTSQs is recommended for measuring patient satisfaction with diabetes treatment. Answers on a 7 graded scale from 0 to 6. In majority, higher score means better outcome.
Absolute and percentage change in EQ-5D-5L (each separate question and VAS) at 3 and 6 months, compared to baseline.
The EQ5D5L questionnaire will be completed during the on-site visits at baseline and at 3 and 6 months. The EQ-5D-5L contains 5 questions, each with a 5 graded answer scale from "I am unable to..." to "I have no problems ...". The VAS scale is a scale from 0-100, where 100 means the best health you can imagine and 0 the worst health you can imagine
Summary of adherence in the population, from baseline to 3 months, from 3 months to end of investigation and from baseline to end of investigation.
Adherence will be summarised at 3 and 6 months by assessing number and percentage of missed basal insulin injections per subject during the period between the visits, compared to the subject's treatment plan. For most subjects, a basal insulin injection is performed at 22.00 in the evening, per standard clinical routine.
Full Information
NCT ID
NCT05284071
First Posted
February 22, 2022
Last Updated
March 23, 2023
Sponsor
Northern Care Alliance NHS Foundation Trust
Collaborators
Brighter AB
1. Study Identification
Unique Protocol Identification Number
NCT05284071
Brief Title
Actiste® Diabetes Management as a Service (ADMS) Clinical Investigation
Acronym
ADMSUK01
Official Title
Actiste® Diabetes Management as a Service (ADMS) - A Clinial Investigation With Insulin Treated Diabetes Patients in the UK
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
March 14, 2022 (Actual)
Primary Completion Date
December 21, 2022 (Actual)
Study Completion Date
December 21, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Northern Care Alliance NHS Foundation Trust
Collaborators
Brighter AB
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The overall aim of the clinical investigation is to confirm clinical performance, treatment satisfaction, adherence and safety of Actiste 1.0 and the Companion
- Page 1 of 5 - app with TBL Backend when used by subjects with diabetes in need of insulin treatment.
Primary objective:
To assess diabetes treatment satisfaction in subjects with diabetes type 1 or type 2 in need of insulin treatment when using Actiste 1.0 and the Companion app with TBL Backend
Secondary objective:
To assess clinical performance and treatment adherence in subjects with diabetes type 1 or type 2 in need of insulin treatment when using Actiste 1.0 and the Companion app with TBL Backend
Detailed Description
This is a prospective, single-arm, post-market clinical investigation to verify clinical performance, treatment satisfaction, adherence and safety of Actiste 1.0 and the Companion app with TBL Backend, referred to as Actiste diabetes management system (ADMS) when used as intended by subjects diagnosed with Diabetes Mellitus Type 1 or Type 2 (T1DM or T2DM). In total, 70 subjects diagnosed with T1DM or T2DM (35 subjects per type) using Glargine U100 basal insulin with or without oral antidiabetic drugs/bolus insulin regimen will be enrolled at 1 site in the UK. Each subject will be evaluated during a period of 6 months. Eight (8) visits are planned for each subject during the clinical investigation, including 3 visits to the study clinic and 5 visits conducted as telephone calls. During the visits, evaluations will be performed to assess blood glucose levels, adherence to the treatment plan, quality of life and treatment satisfaction. Data on blood glucose values, insulin injections and diabetesrelated data from the Companion app and TBL Backend will be shared by the subject.Each participant will be provided with the ADMS, including Actiste 1.0, and the Companion app for their smartphone with the TBL Backend. No comparator will be used.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes type1, Diabetes type2
Keywords
Diabetes Management, HbA1c, Patient, Patient satisfaction
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
13 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Experimental: Single-Arm
Arm Type
Experimental
Arm Description
This is a prospective, single-arm, post-market study to verify clinical performance, treatment satisfaction and adherence, and safety of Actiste 1.0 (Actiste) and the Companion app with TBL Backend when used as intended by subjects diagnosed with T1DM or T2DM.
Intervention Type
Device
Intervention Name(s)
Device: Actiste 1.0 and the Companion app with TBL Backend
Intervention Description
Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes and may improve the patients' adherence to treatment plans. Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes.
Primary Outcome Measure Information:
Title
Diabetes Treatment Satisfaction Questionnaire (change, DTSQc), at 3 months
Description
The Diabetes Treatment Satisfaction Questionnaire (Change, DTSQc) will be completed during the on-site visit at 3 months. The DTSQc is a modified version of the DTSQs designed to overcome ceiling effects and to detect changes in treatment satisfaction. Answers on a 7 graded scale from -3 to 3. In majority, higher score means better outcome.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Percentage and absolute change in HbA1cat 3 and 6 months, compared to baseline
Description
During each on site visit, glycosylated haemoglobin(HbA1c) will be assessed. A blood sample will be taken by the site staff and HbA1c will be assessed per clinical routine at the site.
Time Frame
6 months
Title
Percentage and absolute change in fasting blood glucose at 3 and 6 months, compared to baseline
Description
Fasting glucose will be assessed per standard of care at the investigation site. Fasting glucose will be assessed using the Actiste device at least 4 times in the last 10 days (assessment period) before the investigation visit. The final data will be a mean of the measurements during the assessment period. The data will be extracted by the patient to a PDF file and provided to site 2 days before the visit. Site will ask what day and time the fasting blood glucose data was assessed. The data will also be summarised at the end of the investigation and the interim analysis with data from the Companion app and TBL Backend.
Time Frame
6 months
Title
Absolute and percentage change in DTSQ (Status) at 6 months, compared to baseline
Description
The Diabetes Treatment Satisfaction Questionnaire (Status, DTSQs) will be completed during the on-sitevisits at baseline and at 6 months.The DTSQs is recommended for measuring patient satisfaction with diabetes treatment. Answers on a 7 graded scale from 0 to 6. In majority, higher score means better outcome.
Time Frame
6 months
Title
Absolute and percentage change in EQ-5D-5L (each separate question and VAS) at 3 and 6 months, compared to baseline.
Description
The EQ5D5L questionnaire will be completed during the on-site visits at baseline and at 3 and 6 months. The EQ-5D-5L contains 5 questions, each with a 5 graded answer scale from "I am unable to..." to "I have no problems ...". The VAS scale is a scale from 0-100, where 100 means the best health you can imagine and 0 the worst health you can imagine
Time Frame
6 months
Title
Summary of adherence in the population, from baseline to 3 months, from 3 months to end of investigation and from baseline to end of investigation.
Description
Adherence will be summarised at 3 and 6 months by assessing number and percentage of missed basal insulin injections per subject during the period between the visits, compared to the subject's treatment plan. For most subjects, a basal insulin injection is performed at 22.00 in the evening, per standard clinical routine.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Provision of informed consent
Adult males and females =18 years old
Diagnosed with diabetes I or II, since = 6 months prior to entering the investigation, according to investigator judgement
Currently using insulin as a component of the diabetes therapy, Sanofi Lantus insulin (glargine U100 insulin incartridge or disposable pen)± any form or manufacturer of oral antidiabetic drugs (OADs)/bolus insulin regimen/GLP-1RA
HbA1c 64-86mmol/mol in the last 30 days
Patients using Self-Monitoring of Blood Glucose (SMBG) = 1 month prior to entering the investigation
Able to use smartphone (iOS or Android)independently, according to investigator judgement
Currently using a system compatible smartphone (Android and iOS smartphones: iOS platform versions from 12.0 to 14.x and Android platform versions from 5.1 to 11.x
Able to use the device independently, according to investigator judgement
Exclusion Criteria:
Impaired vision affecting ability to use investigation device or smartphone, according to investigator judgement
Patients using a flash glucose monitor, continuous glucose monitor and/ or insulin pump
Pregnancy or lactation at time of study participation.
Physical or mental impairment affecting subjects' ability to use the device, per investigator judgement
Person not suitable for the investigation according to the investigator judgement.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Adrian Heald, Dr
Organizational Affiliation
Northern Care Alliance NHS Foundation Trust, Stott Lane, Salford, M6 8HD
Official's Role
Principal Investigator
Facility Information:
Facility Name
Salford Royal Hospital Northern Care Alliance NHS Foundation Trust
City
Salford
State/Province
Greater Manchester
ZIP/Postal Code
M6 6HD
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Actiste® Diabetes Management as a Service (ADMS) Clinical Investigation
We'll reach out to this number within 24 hrs